Cannabinoid neuropharmacology across the lifespan: how aging recalibrates risk and benefit.

P A Costa G, De Aquino JP

Open source

DOI
10.1038/s41386-026-02511-1
Published
2026 Jul 30
Container
Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology
Publisher
Not recorded
Open access
unknown

Credibility signals

limited evidence Score 43/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

Cite this work

BibTeX

@article{allodium:10.1038/s41386-026-02511-1,
  title = {Cannabinoid neuropharmacology across the lifespan: how aging recalibrates risk and benefit.},
  author = {P A Costa G and De Aquino JP},
  year = {2026},
  journal = {Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology},
  doi = {10.1038/s41386-026-02511-1},
  url = {https://doi.org/10.1038/s41386-026-02511-1}
}

RIS

TY  - JOUR
TI  - Cannabinoid neuropharmacology across the lifespan: how aging recalibrates risk and benefit.
AU  - P A Costa G
AU  - De Aquino JP
PY  - 2026
JO  - Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology
DO  - 10.1038/s41386-026-02511-1
UR  - https://doi.org/10.1038/s41386-026-02511-1
ER  - 

APA

G, P. A. C., & JP, D. A. (2026). Cannabinoid neuropharmacology across the lifespan: how aging recalibrates risk and benefit.. Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology. https://doi.org/10.1038/s41386-026-02511-1

Source records